ESO-ESMO 2nd international consensus guidelines for advanced breast cancer (ABC2)† - Wikidata - wikimedia - TriplyDB

ESO-ESMO 2nd international consensus guidelines for advanced breast cancer (ABC2)†

ESO-ESMO 2nd international consensus guidelines for advanced breast cancer (ABC2)†

http://www.wikidata.org/entity/Q30317067

about

Targeted chemotherapy with nanoparticle albumin-bound paclitaxel (nab-paclitaxel) in metastatic breast cancer: which benefit for which patients?Patient Management with Eribulin in Metastatic Breast Cancer: A Clinical Practice Guide Dose-Dense Chemotherapy in Metastatic Breast Cancer: Shortening the Time Interval for a Better Therapeutic Index Targeted Therapies Overcoming Endocrine Resistance in Hormone Receptor-Positive Breast Cancer AGO Recommendations for the Diagnosis and Treatment of Patients with Advanced and Metastatic Breast Cancer: Update 2015.Resistance to therapy in estrogen receptor positive and human epidermal growth factor 2 positive breast cancers: progress with latest therapeutic strategies Systemic treatment approaches in her2-negative advanced breast cancer-guidance on the guidelines Endocrine therapy considerations in postmenopausal patients with hormone receptor positive, human epidermal growth factor receptor type 2 negative advanced breast cancers Subcutaneous Trastuzumab for HER2-positive Breast Cancer - Evidence and Practical Experience in 7 German Centers Enhancing Endocrine Therapy for Hormone Receptor-Positive Advanced Breast Cancer: Cotargeting Signaling Pathways Safety of everolimus plus exemestane in patients with hormone-receptor-positive, HER2-negative locally advanced or metastatic breast cancer progressing on prior non-steroidal aromatase inhibitors: primary results of a phase IIIb, open-label, single-Efficacy and safety of everolimus in Chinese metastatic HR positive, HER2 negative breast cancer patients: a real-world retrospective study.Trastuzumab emtansine versus capecitabine plus lapatinib in patients with previously treated HER2-positive advanced breast cancer (EMILIA): a descriptive analysis of final overall survival results from a randomised, open-label, phase 3 trial.Randomized phase II study of nab-paclitaxel as first-line chemotherapy in patients with HER2-negative metastatic breast cancer.Surgery of the primary tumor improves survival in women with stage IV breast cancer in Southwest China: A retrospective analysis.Triple-negative breast cancer: challenges and opportunities of a heterogeneous disease.The value of PET/CT with FES or FDG tracers in metastatic breast cancer: a computer simulation study in ER-positive patients Targeted therapies for ER+/HER2- metastatic breast cancer.A phase I dose-escalation study of eribulin and S-1 for metastatic breast cancer.Efficacy and safety of capecitabine-based first-line chemotherapy in advanced or metastatic breast cancer: a meta-analysis of randomised controlled trials Patterns of resource utilization and cost for postmenopausal women with hormone-receptor-positive, human epidermal growth factor receptor-2-negative advanced breast cancer in Europe Patterns of Care and Clinical Outcomes of First-Line Trastuzumab-Based Therapy in HER2-Positive Metastatic Breast Cancer Patients Relapsing After (Neo)Adjuvant Trastuzumab: An Italian Multicenter Retrospective Cohort Study.Phase II study on the efficacy and safety of Lapatinib administered beyond disease progression and combined with vinorelbine in HER-2/neu- positive advanced breast cancer: results of the CECOG LaVie trial.Cumulative BRCA mutation analysis in the Greek population confirms that homogenous ethnic background facilitates genetic testing.HERMIONE: a randomized Phase 2 trial of MM-302 plus trastuzumab versus chemotherapy of physician's choice plus trastuzumab in patients with previously treated, anthracycline-naïve, HER2-positive, locally advanced/metastatic breast cancer.Breast Cancer-Specific Mortality Pattern and Its Changing Feature According to Estrogen Receptor Status in Two Time Periods Eribulin monotherapy improved survivals in patients with ER-positive HER2-negative metastatic breast cancer in the real world: a single institutional review.Biopsy of breast cancer metastases: patient characteristics and survival Expression of enhancer of zeste homolog 2 correlates with survival outcome in patients with metastatic breast cancer: exploratory study using primary and paired metastatic lesions.The benefit of HER2-targeted therapies on overall survival of patients with metastatic HER2-positive breast cancer--a systematic review Phase II/III weekly nab-paclitaxel plus gemcitabine or carboplatin versus gemcitabine/carboplatin as first-line treatment of patients with metastatic triple-negative breast cancer (the tnAcity study): study protocol for a randomized controlled trial SEOM clinical guidelines in metastatic breast cancer 2015.Fulvestrant 500 mg Versus Anastrozole 1 mg for the First-Line Treatment of Advanced Breast Cancer: Overall Survival Analysis From the Phase II FIRST Study.Disulfiram inhibits TGF-β-induced epithelial-mesenchymal transition and stem-like features in breast cancer via ERK/NF-κB/Snail pathway.A phase II, multicenter, single-arm trial of eribulin as first-line chemotherapy for HER2-negative locally advanced or metastatic breast cancer.β-catenin-independent WNT signaling and Ki67 in contrast to the estrogen receptor status are prognostic and associated with poor prognosis in breast cancer liver metastases Targets for Neoadjuvant Therapy - The Preferences of Patients with Early Breast Cancer.Potential resource and cost saving analysis of subcutaneous versus intravenous administration for rituximab in non-Hodgkin's lymphoma and for trastuzumab in breast cancer in 17 Italian hospitals based on a systematic survey.Subgroup Analyses from a Phase 3, Open-Label, Randomized Study of Eribulin Mesylate Versus Capecitabine in Pretreated Patients with Advanced or Metastatic Breast Cancer Efficacy and safety of trastuzumab combined with chemotherapy for first-line treatment and beyond progression of HER2-overexpressing advanced breast cancer.

P2860

Q26745420-6E9AC296-9E0D-447D-991A-A3F33C92340A Q26749476-54A3A78D-384A-4CA3-ABD0-E3EF5D9A539F Q26751245-7D957E87-0D99-4FA1-A200-368BCD13D593 Q26777734-D2AEF7FC-714F-4441-9098-22AB62C3D61A Q27343148-99ED50CD-E9B6-4C77-9416-636D924468E9 Q28072897-02DE33F8-3883-41A3-907B-7C836A5090ED Q28080469-8A2BD7FB-988D-499D-97FC-806D8C4B1A46 Q28081872-D484E27A-8693-45D1-96F1-97223823CF01 Q28083633-B4613A6A-545D-40B5-B5F3-34A9414E4B65 Q28084585-8E11CB82-DD2B-440E-B7CF-84ED1B000A30 Q33433527-4C21552D-A1A1-475F-BEA6-958B2DE34244 Q33441090-9DF5C845-5B3B-4CF7-920B-DE2B70E5CA20 Q33441996-DBB21A74-FAD6-44D8-9D8C-9689349EA1EF Q33738990-FF6E355C-5B26-4383-A8F1-ADFF65F2CE8F Q33765536-DBDCD407-A2B7-4253-9BC6-B2AE9B566F97 Q33769821-793244D5-3592-4A7B-91C7-5E269F6B2E2B Q35603681-E10E8044-05EC-40D6-883C-375F6B478857 Q35658860-13862FFB-50B7-4F8D-B255-A6F16A3D4510 Q35678690-45C6F440-1F2E-43DB-AAB9-C57CAA491A08 Q35792949-95679669-D4CF-43E1-83CB-F20727082B06 Q35820168-04AF9ACD-CDB3-435F-879B-5733A54FD5FD Q35915735-C058B050-F1FE-46E4-87D4-D6BBE61CC4A4 Q35926639-78B2E78A-0090-4E66-84AD-9D747F825090 Q35983958-667AFFEC-ED3E-4207-8EB1-3995AD10F984 Q36040463-7B079974-1552-47D2-9C8D-EADD1DA10F61 Q36051600-55751006-0D74-411B-B588-31EAD7F0F970 Q36234055-2E67EC3A-A9B5-413F-93E0-B0F3DCA8E834 Q36239768-307B3217-CE7A-4B14-8716-45D377041241 Q36292201-FCF08C4C-C1B6-4C87-BEFB-9B9B50AFDFE9 Q36294151-92B69D5F-0F42-4858-83C5-2DC6ACC3B9E0 Q36379813-EB14D938-F44F-41B4-852F-5ED91E8D33B0 Q36400360-BDBD454B-DA54-43D5-86FF-6271002AFD25 Q36534686-1257614A-D3AB-45C5-B52B-A0EBB89327EE Q36562209-F8FC46F1-FA5C-4721-B98B-F1EF9183C461 Q36614786-BE37BCD7-D17B-4F67-9E95-DA643620779E Q36706395-E4244A86-4313-417A-9F17-AEA065281ADA Q36917634-312E125B-8B72-42D8-BAAE-6C21B2DEAC35 Q36944128-58686CF6-4B43-4F0B-9B92-292994D335A4 Q37052387-7A0AF159-3770-46C4-8F5E-42B613B8C100 Q37104593-EE0D186F-2ED8-4D7E-8839-190C14A1319D

P2860

ESO-ESMO 2nd international consensus guidelines for advanced breast cancer (ABC2)†

http://www.wikidata.org/entity/Q30317067

description

2014 nî lūn-bûn

@nan

2014 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի սեպտեմբերին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

name

ESO-ESMO 2nd international consensus guidelines for advanced breast cancer (ABC2)†

@ast

ESO-ESMO 2nd international consensus guidelines for advanced breast cancer (ABC2)†

@en

type

label

ESO-ESMO 2nd international consensus guidelines for advanced breast cancer (ABC2)†

@ast

ESO-ESMO 2nd international consensus guidelines for advanced breast cancer (ABC2)†

@en

prefLabel

ESO-ESMO 2nd international consensus guidelines for advanced breast cancer (ABC2)†

@ast

ESO-ESMO 2nd international consensus guidelines for advanced breast cancer (ABC2)†

@en

P1433

Q30317067-C914BC9C-10E1-4052-BF5A-3DC9151D36E1

P1476

Q30317067-612F9B68-3A4D-40DD-B369-743B70C57188

P2093

Q30317067-017168FE-7F85-4660-A236-BAE5B87B77D9

Q30317067-0732B3B8-0AB0-4344-893E-8AB0E412C310

Q30317067-08BC6FB5-6C28-4CCA-89F1-8FBBEAFEC137

Q30317067-0CE8656D-8135-43DD-969F-662A9CE5AEA8

Q30317067-13A6AE96-2261-4CAE-AD19-206E64588B04

Q30317067-13E69A0E-E363-4BE8-889C-9874A31415D1

Q30317067-16923744-38B6-4D52-9498-F9A68FDE196D

Q30317067-170F9F86-1FAB-4A23-B59F-326426DD1065

Q30317067-1B5BF1CA-C63B-4423-AE41-0B8BD83EFD90

Q30317067-2E03CC1B-A57B-4DEF-847B-9E0A5FB94694

P2860

Q30317067-0052FFA9-FB3E-49F1-8631-C7E09351BF9C

Q30317067-01F94E42-F72D-447F-87D1-12DCAF170C80

Q30317067-03E0C687-8841-4E62-B37F-093CCC591B0C

Q30317067-08995634-8882-42E4-8E3F-E1735DAD4CEB

Q30317067-0BA5B648-3445-4A9D-95F0-75EB0665A8CC

Q30317067-0E364228-651F-4B45-9C38-B9F9F91F2922

Q30317067-12D93107-585E-4F43-AC06-AB365C9ACFCC

Q30317067-1312FE25-8982-407C-90E7-5277F664168C

Q30317067-1681D7D6-0BE9-441D-8223-C3B1C2E19B4D

Q30317067-179AD03E-AE04-483D-9DDA-FA9051D2DC29

P304

Q30317067-57F060B2-D322-4F61-921E-FC733A010EC6

P31

Q30317067-587FCA01-9BE2-4E8C-B906-E0FCBC28A051

P356

Q30317067-C07CD5B5-5FEE-411A-825E-8B65326F238F

P433

Q30317067-D21B358E-615C-4C41-991A-238B541451EB

P478

Q30317067-B491B504-0A65-4C3B-B48D-1BF60E7D07A4

P50

Q30317067-5833C928-334E-4453-A729-87504B121172

Q30317067-6DE3CE7D-2E79-4E87-9D73-873E5FF90A11

Q30317067-84CA8AF1-0517-4D7B-BD99-D88A830129CD

Q30317067-867499A7-380B-4585-838E-CB788751BC99

Q30317067-9ED28149-8BA6-45E4-A789-E6FE4977CE55

Q30317067-B3F9A724-1D74-4AEE-9983-277BC5B0AE2B

Q30317067-D74B81CE-393A-4917-AEA5-0E566C0ADCCA

P577

Q30317067-A1CA39E6-82B7-4E25-AEC2-0F10D9BD2F4C

P5875

Q30317067-BA8AAE14-6631-4B67-AACC-5AAC93F0ECF3

P698

Q30317067-EC0A4265-DE8F-43B8-AFBD-AD903F47DC46

P932

Q30317067-495FC0E8-3A30-4D8B-B02B-C6D75CA8FFE4

P356

P1433

Annals of Oncology

P1476

ESO-ESMO 2nd international consensus guidelines for advanced breast cancer (ABC2)†

@en

P2093

A Costa

http://www.w3.org/2001/XMLSchema#string

A Goldhirsch

http://www.w3.org/2001/XMLSchema#string

A Partridge

http://www.w3.org/2001/XMLSchema#string

B Kaufman

http://www.w3.org/2001/XMLSchema#string

B Xu

http://www.w3.org/2001/XMLSchema#string

C H Barrios

http://www.w3.org/2001/XMLSchema#string

C Hudis

http://www.w3.org/2001/XMLSchema#string

C Thomssen

http://www.w3.org/2001/XMLSchema#string

C Vrieling

http://www.w3.org/2001/XMLSchema#string

D Fenech

http://www.w3.org/2001/XMLSchema#string

P2860

Combination versus sequential single agent chemotherapy for metastatic breast cancer

Aromatase inhibitors for treatment of advanced breast cancer in postmenopausal women

Inflammatory breast cancer: what we know and what we need to learn

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer.

Trastuzumab emtansine for HER2-positive advanced breast cancer.

Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer

Neoadjuvant anastrozole versus tamoxifen in patients receiving goserelin for premenopausal breast cancer (STAGE): a double-blind, randomised phase 3 trial.

National Cancer Institute Patient Navigation Research Program: methods, protocol, and measures.

Impact of the addition of carboplatin and/or bevacizumab to neoadjuvant once-per-week paclitaxel followed by dose-dense doxorubicin and cyclophosphamide on pathologic complete response rates in stage II to III triple-negative breast cancer: CALGB 40

P304

1871-1888

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1093/ANNONC/MDU385

http://www.w3.org/2001/XMLSchema#string

P433

10

http://www.w3.org/2001/XMLSchema#string

P478

25

http://www.w3.org/2001/XMLSchema#string

P50

Elżbieta Senkus

Prudence Francis

Joseph Gligorov

Sharon H. Giordano

P577

2014-09-18T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

268098278

http://www.w3.org/2001/XMLSchema#string

P698

25234545

http://www.w3.org/2001/XMLSchema#string

P932

4176456

http://www.w3.org/2001/XMLSchema#string